300 mg double-blinded secukinumab

( DrugBank: Secukinumab / KEGG DRUG: Secukinumab )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
271	強直性脊椎炎	1

271. 強直性脊椎炎

臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03350815 (ClinicalTrials.gov)	March 13, 2018	31/10/2017	Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Esc ...	A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 1 ...	Ankylosing Spondylitis	Drug: 150 mg open-label secukinumab;Drug: 150 mg double-blinded secukinumab;Drug: 300 mg double-blin ...	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	322	Phase 4	United States

First Previous1Next Last